Carole Sable

Dr. Carole Sable has been a member of the board since April 2023. She is also a member of the corporate governance & nomination committee.

Dr. Sable is an independent consultant in drug development and portfolio strategy. She has more than 30 years of experience in the field of infectious diseases, both as a physician and in senior positions in the pharmaceutical industry. From 1993 to 1995, she was assistant professor of internal medicine, infectious diseases at the University of Virginia Health Sciences Center, Charlottesville. From 1995 to 2007 and from 2010 to 2013, she worked at Merck & Co in the US in different functions including executive director, clinical research, infectious diseases and neurosciences and vice president, therapeutic area development lead, neuroscience. Dr. Sable served as chief medical officer of Novexel SA (France) from 2007 to 2010, of Scynexis Inc. (US) from 2014 to 2015, of Revolution Medicines Inc. (US) from 2015 to 2016 and of Vitae Pharmaceuticals Inc. (US) in 2016.

Dr. Sable acts as a scientific advisor to CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator and to GARDP (Global Antibiotic Research & Development Partnership) and is member of the Novo Repair SSB.

Dr. Sable holds a bachelor of science in biology from the University of Scranton and a doctorate of medicine from the Jefferson Medical College, Philadelphia. Dr. Sable completed her residency in internal medicine and fellowship in infectious diseases at the University of Virginia.